Reunion Neuroscience is a technology company.
Reunion Neuroscience has raised $130.0M across 1 funding round.
Reunion Neuroscience has raised $130.0M in total across 1 funding round.
Reunion Neuroscience is a clinical-stage biopharmaceutical company developing next-generation psychedelic-inspired therapeutics to treat underserved mental health disorders, such as postpartum depression (PPD) and adjustment disorder (AjD).[1][4] Its lead product candidate, RE104, a patented 4-OH-DiPT prodrug, targets safe, fast-acting, short-duration relief for PPD in the ongoing RECONNECT Phase 2 trial and AjD in cancer patients in the planned REKINDLE Phase 2 trial, while a discovery-stage asset, RE245, advances as a non-psychedelic serotonergic neuroplastogen for chronic treatments.[1][4] The company serves patients with limited treatment options, addressing unmet needs in mental health by enabling rapid return to daily activities, and has shown growth through a $103 million Series A financing in 2024 co-led by MPM BioImpact and Novo Holdings, funding clinical expansion.[1][3]
Founded in 2022 and based in Ontario, Canada, Reunion Neuroscience emerged from prior iterations, transitioning to a private company in August 2023 under CEO Greg Mayes, who previously led a take-private acquisition.[3][5] Mayes, with extensive neuroscience drug development experience, refocused the team on psychedelic-inspired solutions after the company went private, enabling a transformative $103 million Series A in May 2024 to support RE104's Phase 2 trials.[1][3] Early traction included de-risking investments by advancing RE104 for PPD and mental health distress in cancer patients, dispelling psychedelic stigma through rigorous science, and securing cornerstone funding from MPM BioImpact.[3]
Reunion Neuroscience rides the wave of psychedelic medicine resurgence, targeting mental health crises where traditional antidepressants fall short, amid growing acceptance of serotonergic therapies.[1][4] Timing aligns with regulatory progress in psychedelics and rising demand for rapid, tolerable treatments for PPD—affecting 1 in 7 mothers—and AjD in cancer patients, fueled by post-pandemic mental health awareness and investor interest in neuroplastogens.[1][3] Market forces like unmet needs in neuropsychiatry and biotech funding for de-risked assets favor Reunion, as it influences the ecosystem by pioneering short-duration options and presenting at forums like the 2025 Neuroscience Innovation Forum, potentially accelerating FDA-approved innovations.[1]
Reunion Neuroscience is poised to advance RE104 through RECONNECT topline data and initiate REKINDLE for AjD, with RE245 entering preclinical milestones in 2025, supported by its Series A runway.[1][2] Trends like psychedelic destigmatization, AI-driven drug design, and expanded insurance for mental health therapies will shape its path, potentially evolving its influence from niche innovator to leader in serotonergic treatments. As a post-privatization biotech with strong clinical momentum, it exemplifies resilient growth in neuropharma, revolutionizing care for millions underserved by legacy options.[1][3]
Reunion Neuroscience has raised $130.0M in total across 1 funding round.
Reunion Neuroscience's investors include General Catalyst, MPM Capital.
Reunion Neuroscience has raised $130.0M across 1 funding round. Most recently, it raised $130.0M Series A in September 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2025 | $130.0M Series A | General Catalyst, MPM Capital |